A study in the
online edition of the journal AIDS shows that the
anti-HIV drug Viread, when applied as a microbicide
gel to block HIV infection, is safe and
well-tolerated, Reuters Health reports. Researchers at Brown
University studied 84 women, 24 of whom were
HIV-positive, who used the Viread gel daily for two
weeks. The study showed that the gel was well-tolerated,
with only mildly adverse reactions reported. Among the
HIV-positive women, no new mutations were detected in
their virus that would convey resistance to Viread or
to any other anti-HIV drug. About 94% of the women
said they would definitely or probably use the gel if it
were available on the market to protect themselves
against HIV.
Researchers say
the Viread gel may be effective in preventing HIV
infections by shutting down the virus's ability to
replicate in the body. The gel, currently being tested
only in heterosexual women, also could be useful for
preventing HIV infections among gay men who engage in
anal sex, some AIDS experts believe.
Clinical trials
are currently under way in New York City and India to
gauge the effectiveness of the Viread gel in preventing HIV
infections. Studies also are being conducted in the
United States, Thailand, and Africa to determine if
daily use of Viread pills is effective in preventing
HIV infections. (Advocate.com)